Based on early studies, it was hypothesized that expression of Fas ligand (FasL) by tumor cells enabled them to counterattack the immune system, and that transplant rejection could be prevented by ...
New in vivo evidence confirms that tumor-expressed Fas ligand ... immune effector cells. A recent report demonstrated that murine AK-5 tumor cells transiently upregulated FasL when grown in ...
A new clinical study shows that an inhibitor of Fas ligand (FasL), also called CD95 ligand (CD95L), led to a faster recovery ...